22 nd February Utilizing big data to enhance patient recruitment

Transcription

1 22 nd February 2017 Utilizing big data to enhance patient recruitment

2 Overview Barriers to recruitment success Current solutions to overcome recruitment barriers Outsourcing (3 rd Party Vendors, CROs) Feasibility Surveys Utilizing publicly available data (Big data, small and complex data) Identifying sites and KOLs What is the Competitive Landscape Consolidating public and private data What is truth?

3 Barriers to recruitment success Inability to select appropriate sites????? Effective competitive landscape Analysis Potential patient pool decreases by 90% Complex Protocol Design Projected Lasagna s law

4 Current solutions to overcome recruitment barriers Feasibility Surveys and direct contact with KOLs and Sites - Past performance - Face to Face / Telephone contact - Questionnaire Outsourcing to externals entities - CROs - External vendors

5 Current solutions to overcome recruitment barriers Feasibility Surveys and direct contact with KOLs and Sites - Past performance - Face to Face / Telephone contact - Questionnaire Past Experience No Experience Good Sites Bad Sites

6 Outsourcing to External Entities CROs Big Pharma, Small Pharma and everyone in between Loss of control of project coordination Inherent bias toward frequent clients and larger trials Can do attitude that will meet desirable recruitment rates Professional standards and focus not in line Profit driven Big Pharma Small Pharma

7 Outsourcing to External Entities 3 rd Party Vendors Vendor 1 Vendor 2 Vendor 3 Multiple Gaps & Overlaps in vendors data Clinicaltrials.gov accounts ~65% of all trials 20+ trial registries 5+ drug registries All of PubMed Learned Societies Lack Standardization and Quality

8 Utilizing publicly available big data WWW Trials, Drugs, MOAs, Pubmed and Learned Societies Mapping Data mining and semantic linking > 20 Clinical trial registries > 5 Drug data banks Numerous Learned Societies (ASCO, ESMO, ASH ) Perform mapping to relevant disease hierarchy ensuring Standardization and Quality Insightful Analytics with low user threshold Trial Country Site PI Competition

9 Identifying Sites and KOLs

10 Identifying Sites and KOLs Trials Trial Site A Trial Site B Trial Site C PI network Geographical Spread of Cardiovascular Sites Trial Site X Trial Site Y Trial Site Z PI network 30% 24% US EU BRIC Rest of World Trial Site α Trial Site Ω Trial Site β PI network 12% 34%

11 Identifying candidate KOLs

12 Identifying candidate KOLs Investigator Trial Experience New Investigators in Cardiovascular Disease ( ) % 1 study 43% 2 studies 3 studies 6% 4 studies # of Investigators # of Trials 9% 5 studies % Other Investigators New Investigators Number of trials

13 Competitive landscape Scenario Multiple sponsored clinical trials in the field (Immune Oncology) Outsourced/planning to outsource to CRO Identify/validate the selected site locations for opportunity Lung Cancer PD-1/PD-L1 Phase 2

14 Competitive landscape Nivolumab Atezolizumab Durvalumab Pembrolizumab 77 Trials Across 4 sponsored IO Drugs

15 Competitive landscape Nivolumab Atezolizumab Durvalumab Pembrolizumab 77 Trials Across 4 sponsored IO Drugs

16 Competitive landscape Nivolumab Atezolizumab Durvalumab Pembrolizumab 77 Trials Across 4 sponsored IO Drugs

17 Competitive landscape Break down of shared & non-shared sponsor sites Analysis of site types Nivolumab Atezolizumab Durvalumab Pembrolizumab 77 Trials Across 4 sponsored IO Drugs

18 Consolidating public and private data WWW Trials, Drugs, MOAs, Pubmed and Learned Societies Mapping Proprietary Client Data Mapping Trial Country Site PI Competition

19 Recruitment Delays are not as large as you would think 2012

20 Recruitment Delays are not as large as you would think Study timelines are often extended, and challenges to patient recruitment account for up to 45% of study delays. Recruitment issues are responsible for 42% of study delays. What is true?

21 Trial Delays in Oncology

22 Trial Delays in Pain

23 Trial Delays in Diabetes

24 Thank you Kristof Geentjens Technical Product Manager Jonathan Crowther PhD Strategic Analyst, Oncology